Valuation: Atossa Therapeutics, Inc.

Market Cap 21.16M 18.97M 17.34M 15.83M 29.83M 1.99B 30.77M 209M 83.35M 1.06B 79.41M 77.71M 3.35B P/E 2026 *
-0.57x
P/E 2027 * -0.76x
Enterprise Value 21.16M 18.97M 17.34M 15.83M 29.83M 1.99B 30.77M 209M 83.35M 1.06B 79.41M 77.71M 3.35B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+4.95%
1 week-2.30%
Current month-2.30%
1 month-13.47%
3 months-12.40%
6 months-63.45%
Current year-76.05%
1 week 1.98
Extreme 1.98
2.4
1 month 1.98
Extreme 1.98
3.12
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
14.85
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
42.22
10 years 1.7
Extreme 1.7
468
Manager TitleAgeSince
Chief Executive Officer 75 2009-03-31
Director of Finance/CFO 50 2025-10-13
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Chairman 75 2009-03-31
Director/Board Member 64 2009-03-31
Director/Board Member 79 2011-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
5/12/26
Ensisheim Partners LLC
OtherCompany 0 0% -
5/12/26 Free

Director

10,000 0.1161%
5/12/26 Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
+4.95%-2.30%-82.65%-79.22% 21.16M
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average +0.77%+2.70%+42.28%+122.10% 40.58B
Weighted average by Cap. +0.21%+3.40%+53.11%+142.94%

Financials

2026 *2027 *
Net sales - -
Net income -35.3M -31.66M -28.93M -26.41M -49.76M -3.32B -51.33M -349M -139M -1.77B -132M -130M -5.59B -38.03M -34.1M -31.17M -28.45M -53.61M -3.57B -55.3M -376M -150M -1.91B -143M -140M -6.02B
Net Debt - -
Projected Income Statement - Annual - Atossa Therapeutics, Inc.
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
26-11-06 $2.120 +4.95% 34,833
26-11-05 $2.020 -4.72% 75,034
26-11-04 $2.120 -9.01% 70,258
26-11-03 $2.330 +1.30% 26,078
26-11-02 $2.300 +5.99% 65,998
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Atossa Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.120USD
Average target price
19.00USD
Spread / Average Target
+796.23%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Atossa Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATOS Stock